NCT00312650

Doxil and Gemcitabine in Recurrent Ovarian Cancer

A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 24 (planned)
• Sponsor: Women and Infants Hospital of Rhode Island · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine.

Detailed description

This study will evaluate the toxicities of Doxil and Gemcitabine given on an every two week basis. Our hypothesis is that toxicity will be less than that with standard dosing without any negative effect on survival. Patients will also be evaluated with CT scans every 3 months. Toxicity will be assessed with every cycle of treatment. Treatment will continue until toxicity or signs of progression.

Conditions

• Ovarian Carcinoma

Interventions

Type	Name	Description
DRUG	liposomal doxorubicin and gemcitabine

Timeline

• Start date: 2006-04-01
• Primary completion: 2006-05-01
• Completion: 2006-05-01
• First posted: 2006-04-10
• Last updated: 2015-01-12

Locations

1 site across 1 country: United States